




MENTOR™ MEMORYGEL™ XTRA BREAST IMPLANTS ARE

Designed to Perform



RESULTS FROM THE

GLOW%

STUDY*†

We're 100% committed to positive patient outcomes. Our 3-year FDA post approval data from the GLOW clinical trial, across a size range of 250-790cc with an average of 410cc, proves it.

MENTOR™ MemoryGel™ Xtra Breast Implants deliver exceptional patient outcomes, with ZERO rupture, infection, and malposition.

0% Rupture, malposition, wrinkling, infection* **1.5%** Capsular contracture* **3** Year data

100% Commitment to positive patient outcomes

MENTOR™ MemoryGel™ Xtra continues MENTOR's 40-year legacy of always striving for patient safety, product reliability and predictable long-term outcomes.

* For the primary augmentation cohort, not including reoperation. No instances of MemoryGel™ Xtra displacement/malposition or infection were reported at 3 years in any cohort using the Kaplan-Meier estimated cumulative incidence rate.

† Clinical Results of Mentor MemoryGel Xtra Breast Implants from the GLOW Clinical Trial. Amy Alderman, MD, MPH, FACS, et al. *Aesthetic Surgery Journal*. 2023.

#1 GLOBAL BRAND

HELP EACH WOMAN FEEL LIKE THE

Best Version of Herself

WITH BREAST IMPLANTS BY MENTOR

The GLOW Study continues to highlight the advantages of MENTOR Breast Implants.

The GLOW Study:

- 10-year FDA-approved post-approval prospective clinical study
 - 3608 total patients enrolled in the study
- Evaluating long-term performance, safety, and health-related outcomes

We are proud that women who chose MENTOR™ MemoryGel™ Xtra Breast Implants reported high patient satisfaction, including increased social and sexual well-being, one year after implantation.†

† Measurement of patient well being based on measured BREAST-Q score changes from before operation (baseline) to the 1-year follow-up point.

IMPORTANT SAFETY INFORMATION

MENTOR™ MemoryGel™ Breast Implants are indicated for breast augmentation in women at least 22 years old or for breast reconstruction. Breast implant surgery should not be performed in women with active infection anywhere in their body, with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions or are pregnant or nursing.

Breast implants are not lifetime devices and breast implantation is not necessarily a one-time surgery. The chance of developing complications increases over time. The most common complications with the MemoryGel™ Breast Implants include reoperation, capsular contracture, asymmetry, and breast pain. A lower risk of complication is rupture. The health consequences of a ruptured silicone gel-filled breast implant have not been fully established. MRI screenings are recommended three years after initial implant surgery and then every two years after to detect silent rupture. Breast implants are also associated with the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), an uncommon type of lymphoma. An individual's risk of developing BIA-ALCL with MENTOR™ Breast Implants is low based on the incidence of worldwide cases.

Patients should receive a copy of Important Information for Augmentation Patients about MENTOR™ MemoryGel™ Silicone Gel-Filled Breast Implants or Important Information for Reconstruction Patients about MENTOR™ MemoryGel™ Silicone Gel-Filled Breast Implants. Your patient needs to read and understand the information regarding the risks and benefits of breast implants, with an opportunity to consult with you prior to deciding on surgery.

For detailed indications, contraindications, warnings, and precautions associated with the use of MemoryGel™ Breast Implants please refer to the Instructions for Use (IFU) provided with each product, or online at www.mentorwllc.com.

© Mentor Worldwide LLC 2024 EM_MNT_BRST_304317

 **MENTOR™**